ERBB2 and breast carcinoma: Upon an immune reaction, some studies demonstrated that breast cancer cells with HER2 low levels resulted in initiating an immune response to breast cancer through the HER2 receptor, and the HER2 protein level was not the only factor indicating the drug response [41,42].